NSPX DD Package: 1. Company Profile: Inspyr

New Post Public Reply Private Reply Replies (0) Message Board
HighPeaks SHEEPWOLF #44578
1,112
NSPX DD Package:

1. Company Profile:
Inspyr Therapeutics, Inc., formerly Genspera, Inc is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.




2. MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-

MUST WATCH videos about Mipsagargin:

Intro into Mipsagargin by Inspyr(formerly Genspera):

be.com/watch?time_continue=4&v=HMasGEnMysA


NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:

be.com/watch?feature=youtu.be&v=fIgp4n3Itzo


Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI:

https://m.youtube.com/watch?v=4lTX7y16pt0


Mipsagargin latest update as of June 2018 (with other patent info):
https://adisinsight.springer.com/drugs/800030883

https://patents.justia.com/assignee/inspyr-therapeutics-inc


Q/A with the Doctor behind Mipsagargin:
https://www.reddit.com/r/IAmA/comments/3gqfnn...scientist/



3. Meet our CEO- Chris Lowe:


https://m.youtube.com/watch?v=LIfsnZP6W2o

Chris Lowe joined FLG in 2014, serves on the Firm’s Management Committee and was elected Co-Managing Partner in 2018. Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies.  Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees.  Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite.  In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits.
During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations.  As VP and CAO, he drove a parallel M&A and IPO path resulting in the sale of Peninsula Pharmaceuticals to Johnson & Johnson for over $300M in 2005, including the design of a tax efficient spinout for assets which were undervalued by Johnson & Johnson.  As CFO of Asthmatx, a medical technology company, he actively drove strategic supply negotiations and led the parallel M&A and IPO process resulting in a $50M strategic investment from Olympus Medical and ultimately the sale of the company to Boston Scientific in a deal valued at approximately $400M.  As its Chief Financial Officer, he also took Anthera Pharmaceuticals, a pharmaceutical development company, public in 2010 during the height of the financial crisis, raising over $300M in both the private and public markets during his tenure.
Prior to joining FLG, Chris  recently served as a strategy, financial and management consultant to several public and private companies, assisting them with financings, market due diligence, Wall Street communications, and exits.
Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University.  Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).


4. Most recent NEWS with potential 12 Million Licensing deal with Ridgeway Therapeutics:

Inspyr to License Oncology Related Compounds to Ridgeway Therapeutics Inc.
9/17/18, 8:00 AM
WESTLAKE VILLAGE, Calif., Sept. 17, 2018  Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
https://www.prweb.com/releases/inspyr_to_lice...761201.htm

***This licensing deal does not cover Mipsagargin so there may be another separate deal in the works....


5. Past News Releases or Articles of Significance:

1. Oct 23 2017- Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
https://globenewswire.com/news-release/2017/1...ealth.html

2. Oct 4 2017- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital-Dr. Allison Reiss Initiates Pre-Clinical Study for Atherosclerosis
https://globenewswire.com/news-release/2017/1...pital.html

3. Oct 2 2017- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine-Dr. Cirle Warren Initiates Pre-Clinical Study for Clostridium Difficile
https://globenewswire.com/news-release/2017/1...icine.html

4. Sept 13 2017- Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger- Creating Integrated Company with Proprietary Platform, Broad Pipeline, and Significant Drug Development Expertise
https://globenewswire.com/news-release/2017/0...erger.html

5. Sept 12 2017- Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
https://globenewswire.com/news-release/2017/0...tures.html


6. Aug 4 2016- Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
https://www.businesswire.com/news/home/201608...-Executive

7. Aug 1 2016- GenSpera Announces Name Change to Inspyr Therapeutics[b/]
https://www.businesswire.com/news/home/201608...erapeutics

8. June 9 2015- GenSpera And Cancer-Specific Hand Grenades
https://seekingalpha.com/article/3245765-gens...d-grenades

9. March 30 2015- GenSpera Contends In The Prodrug Space, Reaching Phase 3
https://seekingalpha.com/article/3039246-gens...ng-phase-3

10. Feb 24 2015 - Genspera's Mipsagargin Phase 2 Results Impress
https://seekingalpha.com/article/2944176-gens...ts-impress

11. Jan 16 2015- ***GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin-First-in-Class Agent is Well Tolerated in Liver Cancer Patients***
https://www.prnewswire.com/news-releases/gens...21471.html



6. Recent Inside significant stake by Hedge Fund Sabby Management:

NEW 13G Filing:
https://www.otcmarkets.com/filing/html?id=130...p-vXMxZ1yh
 
Sabby Management, LLC is an employee owned investment manager. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity and alternative investment markets of the United States. The firm primarily invests in options. It also makes private investments in public equity. The firm employs a opportunistic and event-driven strategy to make its investments. It also employs fundamental and quantitative analysis. The firm invests in the healthcare sector, including the biotechnology and pharmaceutical sector. Sabby Management, LLC was formed on June 6, 2011 and is based in Upper Saddle River, New Jersey.



7. Share Structure:

O/S= 46,858,929 As of November 26,2018
A/S=150,000,000 As of November 26,2018

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Gate Ventures Backs Japanese Web3 Gaming Innovator double jump.tokyo

Updated Category News Views 276

Gate Ventures Invests in double jump.tokyo Gate Ventures is making a significant impact in the blockchain and gaming sectors with its latest investment in double jump.tokyo Inc., a prominent player in Web3 gaming based in Japan. This strategic investment is part of a larger $10 million funding round led by SBI Investment. This backing represents more than just financial...

Continue Reading
Insights from Gridwise's Gig Mobility Report Highlight Trends

Updated Category News Views 1754

Gridwise Annual Gig Mobility Report Highlights The gig mobility industry is encountering significant challenges as economic conditions evolve. Consumers are feeling the pinch from rising prices, leading to resistance against fare increases. Moreover, driver wages are stagnating, which is causing utilization rates to remain low. As platforms strive for profitability, this...

Continue Reading
Esquire Financial Achieves Historic Stock Surge to $81.89

Updated Category News Views 124

Esquire Financial's Stock Reaches New Heights Esquire Financial Holdings Inc (NASDAQ: ESQ) has celebrated a remarkable achievement as its stock price reached an all-time high of $81.89 recently. This milestone reflects the company's strong financial health and market position, boasting a market capitalization of approximately $638 million. The surge in price signals a...

Continue Reading
Deck Commerce Shines as a Leader in Omnichannel Management

Updated Category News Views 199

Deck Commerce Emerges as a Leading Innovator In the competitive landscape of order management systems, Deck Commerce stands out as a beacon of innovation and excellence. Recently recognized by QKS Group's SPARK Matrix™ for 2025, the company has secured its position as both a leader and emerging innovator in the field. This accolade reflects Deck Commerce's dedication to...

Continue Reading
Porsche Penske Motorsport Celebrates Historic Victory

Updated Category News Views 343

Porsche Penske Motorsport Celebrates Historic Victory Porsche Penske Motorsport has achieved remarkable success at the prestigious 24 Hours of Daytona, clinching its second consecutive win. As the race unfolded, the familiar faces of Felipe Nasr, Nick Tandy, and Laurens Vanthoor led the No. 7 Porsche 963 to victory, marking a milestone as Porsche secured its 20th overall...

Continue Reading